Skip to main content
ANAB $46.63 -1.62%
ANAB logo
ANAB · Anaptysbio, Inc
Track ANAB — free
$46.63 -0.77 (-1.62%) At close · Nov 20
Market Cap
$1.39B
Shares
29.90M
Volume · Nov 20 432.48K Avg daily vol (3M) 494.29K
All webcasts

Conference · 2026-11-17

Anaptysbio, Inc (ANAB) November 17, 2026 Conference Transcript

Concluded Nov 17, 2026 Audio replay
Nov 17, 2026 29:47 39 turns
Period
2026-11-17
Runtime
29:47
Sources
2 artifacts

Transcript & audio

29:47 Audio
Madeline Lee Analyst — UBS

I'm Madeline Lee, and I'm a member of the U.S. biotech team here at UBS. I'm joined here today by Dan Vega, CEO at Anaptis Bio. Dan, thanks for joining us today.

Dan Vega CEO

Pleasure to be here. Thank you.

Madeline Lee Analyst — UBS

Second time today. So, obviously, there's been a lot of change at Anaptis over the last year. You spun out the biotech operations. Maybe we could start with, if you could just give us a quick overview of where the company stands, a rationale for spinning that out, and, yeah, we can start there.

Dan Vega CEO

Perfect. Right. About a year or so ago, we announced the intention to spin off or perform our operations from Anaptis. We successfully completed that transaction on April 20th of this year, so six, seven months ago. And the transition's gone really well, and I would say it's long from complete at this point. Today's Anaptis looks very, very different than prior to the separation. We've transformed the company into a virtual organization. We have zero employees. It's contractor-based. We have a full-time CFO. I'm part-time running the company. We have a group of folks that support on the finance team keeping things afloat. And it's not an overly complicated business to run where your two core assets are two royalty threads, one for a product called Jumperly, which is sold by GSK, approved in dozens of markets as a P2-1 antagonist. The second program is an IL-36 receptor antagonist that was out-licensed to Vanda, and as time continues to creep on here, we are about a month away from the PDUFA for hopeful approval in a disease called GPP, Generalized Pustular Psoriasis, which is a rare derm disorder. So exiting this year, hopefully we'll have two different royalty threads at our commercial stage. We're running the company at a very high EBIT margin, as you can imagine, in this type of a framework, greater than 95% EBIT margins, less than $10 million yearly operating expenses. So virtual royalty-based company designed to protect and manage the royalty threads of the two assets I described.

Madeline Lee Analyst — UBS

Got it.

Dan Vega CEO

Exciting and very, very different.

Madeline Lee Analyst — UBS

Indeed, indeed. I think that anything else that's out there. Yeah. Could you remind us maybe just of the economics on Jim Perley? How do you think about the growth trajectory of the drug from here? Yeah, just starting there.

Dan Vega CEO

Yeah, so GSK recently announced their third quarter results, and to date, generally sold over a billion dollars of revenue through calendar year 2026. The drug is growing approximately 30% year over year. So at high growth stage, fueled by a launch in endometrial cancer about two plus years ago in the U.S. and following on in Europe a year and a half ago. And then very recently, not in the Q3 numbers, we had an approval in DMMR rectal cancer, first immunotherapy approved in rectal cancer to date. So I think broad growth prospects, we often cite from our company really, at least to date, how GSK is guiding around the asset. So they've discussed upwards of 2 billion pounds or $2.7 billion in peak monotherapy sales tied directly to endometrial cancer and rectal cancer. So I think a lot of upside from here to go, just in the commercial stage. The label are indications that are approved as of today. As it relates to the actual royalties we receive on those revenues, we have a pretty almost exponentially tiered royalty stream. So up to a billion dollars in revenue, we receive 8% royalties. Then it triggers up to 12% to $1.5 billion of calendar year revenues, 20% up to $2.5 billion, and then 25% beyond there. So in the fourth quarter, and this is what's great about the way a royalty business works, as Gemperly grows, our revenues are going to grow, again, continually on almost an exponential rate on a relative basis as you cycle through a calendar year. Or said differently, since they've already cleared a billion dollars through this year, all the Q4 revenues that we ultimately will receive will be at a 12% royalty rate or even potentially a 15% royalty rate, depending on how well the GSK performs in Q4.

Madeline Lee Analyst — UBS

Got it. Yeah. Could you remind us as well the anticipated loss of exclusivity, including any potential extensions? And I think the language in your 10K is until the last to expire relevant patents. So I did want to touch on, I think that they recently initiated a trial of the sub-Q version of Jim Pearlie in collaboration with Alteogen. So would those patents covering the sub-Q formulation also sort of qualify for that last to expire?

Dan Vega CEO

Yeah, good question. So the history of NAPTIS, NAPTIS has been around for over 20 years. So the assets that we're talking about, these royalties we have, were from homegrown or discovered programs over time. And the origination of GEMPERLE, or the PD-1 antagonist, was from an out-licensing deal back in 2014 when it was really just a drug candidate in the earlier days of IO. So, when we talk about the patent life, we were obviously directly involved as a company in the composition of matter of this IP in the earlier days of. Common ways to think about extending IP life cycle. What's in the public domain that we recite, and this is actually in GSK's yearly filings, is a 2035 composition of matter in the US, 2036 in Europe, and 2037 in Japan. And there is a billy for extensions from that. I think GSK talks about 2038 in their filing. So I'll leave it at that for now. I mean, there's obviously always a lot more complexity that we're aware of, But that's what's in the public domain from GSK. I think what's interesting there, it actually really speaks to the global business that GSK is running. I mentioned earlier where we see the drug approved in the U.S. now in two indications, both endometrial and rectal. In Europe, they received endometrial approval about 18 months ago. They've described 2027 as the year to file and then seek approval or receive approval in rectal cancer in Europe. But Japan is going to be a completely new market where they will go file on rectal cancer as well, and then subsequently on endometrial cancer, really opening up a third frontier for the drug. And Japan, when you look at comps across the oncology space or even within GSK, is usually about 10, plus or minus 10% of the total global royalties. So we have a long-duration asset here, plus or minus 10 years on Jumper alone. For Imsidolumab, the IL-36 receptor antagonist, that goes in the 2040s in terms of that royalty thread. So long-duration asset, and we like to say for right now where we are as a business, there are multiple years in terms of equity growth. Cattle set will read out in terms of additional indications where GSK has already invested in GEMPOLI, both on a monotherapy basis. So then a separate story about how they're thinking about combinations in oncology that would include GEMPOLI. And then as well as imcidolamab. With the upcoming approval and really launch of that drug, multiple years of an equity story here before we would ultimately transition to what we think about as a yield story in terms of cash flow positive and then how do we allocate that capital when cash proceeds are coming in.

Madeline Lee Analyst — UBS

Got it. So you mentioned catalysts for the pipeline, or I guess we can start first with the recent rectal cancer approval, which was approved way ahead of the PDUFA date. Can you sort of walk us through that data, which was presented at ESMO, and maybe touch on how big this indication is, how we should think about how that might affect the revenue trajectory over the near term?

Dan Vega CEO

Yeah. So for some context around rectal cancer, I'll just kind of speak a little about endometrial to relatively size. Endometrial, again, GSK's analysis, has about 40,000 patients in the U.S., Europe, and Japan with endometrial cancer. There's two forms that we are approved for, DMMR and MMRP, that really covers really the totality of what you see within endometrial cancer. It's approved in the front line in combination with chemo and is the only PD-1 antagonist that has an overall survival label. So Keytruda is approved in endometrial cancer, but they did not run a trial that actually showed a delta on survival in this indication, the front line setting. When you look at rectal cancer in DMMR, which is about 10% or so of all rectal cancer, so the smaller subset, So MSK, MSK, Morosel and Kettering Cancer Center, ran a phase two trial where they showed a 100% overall response rate. So it was an IST, self-initiated. GSK saw those results and then went and ran a phase two pivotal trial. Based on the quality of really the phase two results, the U.S. gave what was new at the time about a year ago, chairman's voucher. So there's only a few of these that are out there, but it allows for a two- to three-month accelerated approval timeline on the submission of interim data analysis. So GSK did have a PIDUFA in February, but when they re-ran this study in a much longer global trial, they saw 71% complete response rate, which is just absolutely exceptional for the patients here, with a label that extends out over six months. They have now decided to initiate a longer-form trial where you continue to get more cycles of the drug, so that initiates shortly or recently initiated. But the approval happened a few weeks ago, months ahead of the PDUFA date, given the chairman's review voucher, and they will be submitting in Europe in the first half of next year and Japan soon thereafter, as I described earlier. So exciting new revenue story. So said another way, all the on-label sales for the drug to date for the billion dollars this year have all come from endometrial cancer, principally in the United States and then recently with reimbursement in Europe. So it really speaks to how much upside there is in the story just in these indications. We're still in the earlier innings of endometrial cancer, particularly on a global basis. And then the very first inning here, commercially on rectal, we will see revenues in the drug has been launched in the United States from late October through December of this quarter.

Madeline Lee Analyst — UBS

Got it. And could you just help us maybe size? How big is that indication, just as we think about our models and how that might affect the numbers?

Dan Vega CEO

It's a multi-hundred million dollar revenue opportunity, so it's not as large as endometrial, but as I said earlier, I think the way GSK guides, which we'll stick to for now, is a peak sales opportunity here for Gemperly across endometrial rectal in the U.S., Europe, Japan, and likely China. of well over 2 billion pounds or closer to $2.7 billion at current exchange rates when you look at this in totality.

Madeline Lee Analyst — UBS

Right. I guess just zooming in on that guidance a little, I think in recent earnings calls, they've maybe broken that out into around one half or one billion for endometrial, the other half being for colorectal and head and neck. I guess that leads into my next question, which is around the catalyst flow. Some of those catalysts aren't really reading out until 2028. So, we think about that guidance being by 2029. I guess, how do you appreciate it's not your guidance? Right. Think about that timing.

Dan Vega CEO

Yeah, and it's an interesting situation we're still in, and we'll talk a little bit later about some of the litigation with the company as well. But sticking with the way they're describing the opportunity, they have not said by 2029. We've added that estimate on based on our own work and modeling and how we see the sales projections. I think when you compare that to consensus Wall Street modeling, and this actually gets into one of the challenges with GSK and oncology, they are not known as a GSK oncology powerhouse. I think when you look at their mid-longer term consensus estimates from Wall Street, they are significantly discounted from what GSK is guiding to over the next four or five-year period, and at least what we see in terms of uptake in the markets in U.S. and Europe. But what I can see here and say is across the consensus, almost nobody models Japan, which is a little bit why I'm describing that today. You add 10% on top of the global sales. That's a meaningful number. China, usually about 5%, 6% of the global markets in China. We know they're filing there. They're talking about that publicly, but no one's modeling it. So I think there's a lot of room here for global expansion in the way people are thinking about the forecast, And that really is what ties together a lot of the work done backwards looking today with just... Modest growth rates in the U.S. versus what's happening real-time in Europe. Reimbursement didn't really begin here across the core countries until the beginning of this year. So U.S. was growing at 30%, 40% quarter over quarter this year. U.S. has been plus or minus 10%. That's conducive to a drug that's now been on market in the U.S. for about two years. Rectal cancer is going to be another infusion of growth in the U.S. market. So I think you're going to continue to see a drug growing at 20% or 30% just from those basic U.S. and European regions without even thinking about Japan. But when you start adding on global expansion for a company that obviously has the resources to go launch in these markets and they're there in other therapeutic areas, you can start to get to 2 billion, 2.5 billion pounds over the next few years pretty easily from a modeling perspective.

Madeline Lee Analyst — UBS

Got it. That makes sense.

Dan Vega CEO

And it's supported by the top-down numbers I was talking about earlier as well in the two different disease states.

Madeline Lee Analyst — UBS

We do have our GSK analyst in the room, so hopefully he's with us. That as well. Yeah, I guess, could you just remind us then the key pipeline milestones we're looking for, which, as you said, could be upside to consensus numbers as well.

Dan Vega CEO

I'll give credit to GSK where I think it's worth it in these monotherapy indications. They acquired Tesaro. It was about eight, nine years ago at this point. They launched GEMP early in 2021. Tessara was taking a very specific strategy here to go where Catruda is not a star, right? I mentioned earlier in endometrial cancer, the survival's not on the label. Rectal cancer is a big market. It's not a $20 billion market like lung cancer, but Couture is not playing there. In head and neck cancer, there's a lot of ways to slice and dice this market. Head and neck cancer be curative via surgery in certain populations, and so then there's also the treatment or pre-treatment with PD-1s before or after procedures, and where GSK is focused is a very specific niche where PD-1s have not been successfully tested, but there are also a lot of, I think, interesting analysis that's been done of, in some populations, where you're coming in and out of before or after chemo relative to surgery, where there is robust data. So they're actually going after a specific sub-market where the data suggests PD-1s would be successful, and there's nothing else approved. That trial is ongoing in terms of recruitment, and they've guided to a readout in 2028, as you were suggesting earlier. There's two trials ongoing in DMMR and MMRP colon. In DMMR colon, that's a phase three trial, and MMRP colon, that's a phase two trial. You brought up earlier about differences in guidance. I will acknowledge that depending on who's speaking on behalf of the company and when they're doing it, you've heard slightly different things. We're sticking right now with the two core markets that were stable for multiple years that came out of really the mouths of now multiple CEOs at the company with how we're thinking about the markets. It supports what we're doing also internally.

Madeline Lee Analyst — UBS

Got it.

Dan Vega CEO

And that's all, but again, importantly on a monotherapy basis or monotherapy plus chemo.

Madeline Lee Analyst — UBS

Got it. Yeah. So I guess following off of that, that's monotherapy. Can you tell us about combinations? What's GSK's strategy overall for GMPRILI in combination?

Dan Vega CEO

We've had a long, I think, successful history of watching them in combinations with GMPRILI. So as an example, in lung cancer, they ran a trial where obviously PD-1 has been very successful in lung cancer, changed the whole paradigm of thinking about patients and survival in lung cancer. They ran a study, actually Tesaro initiated, but GSK ran a study called the Perla study, where it was head-to-head with Keytruda, and they actually saw numerical superiority against Perla in frontline lung cancer. Now, that was an established market, and from there, GSK has taken a number of different strategies to run programs in combination. That includes CoStar, which did not work in the second line with another IO therapy, and that's consistent with everyone else in the field. Those combos just didn't work. They were looking at anti-Tigit in Frontline, where they took the Starlamab or Jemperly plus a Tigit against Catruda. Those are natural differentiation. So they've been at this for a while. The latest, and I think really all the oncology companies are looking at ADCs in combinations with IOs, and GSK is taking an approach there. Some cases with GEMPRLI and some cases with other PD-1s that are in these markets. That is the basis of the litigation we have with GSK. We are full supporters of GSK developing GEMPRLI with commercial reasonable efforts in any combinations, whether that's in lung cancer where GEMPRLI is not approved or endometrial cancer where it is. What we believe our relationship and contractor rights suggests is they do not have the ability to go develop their ADCs with... Other PD-1 antagonists. We think we have an exclusivity provision that protects against that. We also don't think it's commercially reasonable to spend a dollar. Out of their balance sheet on combos that are with other PD-1s at the expense of doing that with Jemperly. So that's the source of some litigation that's out there. We have gone to trial on this. There were closing arguments about a month ago or so, and we do expect a judgment on the outcome of this litigation within the next one to two months.

Madeline Lee Analyst — UBS

Right. Well, you led right into my next topic. So I think it merits maybe a little more time to discuss specifically the design of two trials, the BEHOLD trial in endometrial cancer, and then the EMBOLD trial in in-lung cancer, if you could just maybe highlight on a high level why those were designs that you flagged internally at Anaptis. When those were discovered.

Dan Vega CEO

Yeah, so... What GSK is doing, which is rational in a lot of ways, just is in violation of our contract, is they're looking at these combinations of B7H4, B7H3, depending on the different settings, and you've now named them both. So the Imbolc study is a B7H4 plus PD-1 combination trial. You initiate patients on a PD-1, you know, again, Jemperle and Contruder both approved in this field. So you can initiate an either, and then you're adding on the B7H4 program to extend prior to progression-free survival. So that would be in the frontline setting. So you have really a head-to-head of the two PD-1s with an add-on of B7H4. So the B7H4 wins no matter what if the trial is successful, but you're really competing gemperly or pitting gemperly against Catrude in that trial design. It's very different than... Contruda has a control arm. And, uh, Jemperly with B7H4 being add-on to Jemperly. That's, that's the heart of one of two trials in the litigation. Behold is a broader based trial in multiple subindications of lung cancer, whether non-small cell lung cancer or small cell lung cancer. That's a B7H3 ADC. In both of those settings in the front line, Jemperly is not being used at all in the combinations. So it's a really interesting predicament. They've done a great job of monotherapy. There's no qualms about that. That's not what the litigation is about at all. A lot of what they've done backwards looking, a lot of what we expect in the future is really conditioned on sustained growth or some of the catalysts we were at earlier get to these peak revenues. There's a chance these combos don't even work, but at the end of the day, in endometrial cancer, we don't want to see the market continue to be divided up between Jemperle and Keytruda. If the Jemperly-ADC combo works, and it works really well, we would like to see increased market share by the exclusive use with our PD-1 antagonists. So that just gives you this general context. I think there's protection in monotherapy revenues throughout. If the ADC is used in Jemperly, regardless of the coutured arm, we will still continue to see revenues as royalties from the use of that combination. In a subcutaneous format in the future, it's still subcutaneous. The Starlamab, which is the generic name, we will still see royalties with subcutaneous formulation. So you asked about that a little bit earlier. But the litigation, I think we're in a really good position. We have strong, credible arguments. It's in front of the chancellor in Delaware Chancery Court. And the stakes are really high. I think for our company, if the chancellor sides with us on CRE or on exclusivity, the contractual right is reversion of the drug. So this was written between Anaptis and Tesoro 14 years ago. I'll acknowledge it is not how you would normally do a deal with a big pharma company, but the big pharma company in this circumstance bought the smaller company Tesoro and are living with a contract and a relationship that we put in place with them. So that's something that they own and have to live by. In the event that we get the drug back, I talked earlier, we are a virtual company. We will not be commercializing germplily on a global basis. I testify to this at trial. We will, instead of managing a royalty, we will quickly go to constructing a strategic process to go put this drug in the hands of another party that will focus on the development of Jemperly, not the expense of other assets in the portfolio. And we think we can create a lot of value in doing so. If we lose on litigation... We will be living by the fact that GSK wants to do a lot of development across PD-1s. It doesn't hurt our royalty stream in the shorter term, but I do think it does impact things in the longer term in terms of the maximal opportunity of what the drug should be.

Madeline Lee Analyst — UBS

Got it. So I guess in the... And I think in the transcripts, there is a mention maybe of a pending conversation that you have with someone who might potentially be interested in a rights to Jim Perley. So I can see how that would play out in that scenario.

Dan Vega CEO

There's a lot of oncology companies out there that didn't win in the races in the earlier days between Merck and Bristol. Z has a PD-L1. GSK is a successful drug in Jim Perley. There's a lot of other companies that this would fit well, and we have had discussions with now a number of companies that would be interested in this program.

Madeline Lee Analyst — UBS

Got it. And then I guess in the other scenario, which you sort of mentioned, if you end up with status quo royalties, can you just maybe tell us about what does the future of this company look like? Would you consider bringing in additional royalty streams? Obviously, you also have the Ipsidolumab, but would you sort of change your thinking around how you manage Anaptis as a company if that were the outcome?

Dan Vega CEO

Yeah, so I think, you know, in approximately a year's time, we will have paid down an outstanding non- Thank you. In sending, it's a royalty-backed loan with a group called CIGARD. We'll exit this year with somewhere around $200 million owed on that loan. That loan was put in place prior when we had the operating business to fund clinical development. So that's rapidly being paid down. We anticipate that being paid down in the back half of 2027 based on the current run rate of what we're seeing and growth expected next year in Jemperle. We don't see a lot of risk that we end next year, not cash flow positive. So right now we receive the royalties, and they go right back out to Cigard. We have about $150 million or so on the balance sheet. We have plenty of cash to run this business. We also have a share repurchase plan in place of up to $100 million to buy back stock along the way as we see how the stock's been trading. So we have a lot of flexibility in how we're using the capital we have today given the OPEX is so low. In the last quarter, we spent about $2.2 million on a quarterly run rate basis on OpEx for the company. So in about a year, we become cash flow positive. I think then we have to start making decisions what to do with the cash. The stated strategy, which we don't have an intention today of changing, is to manage and protect the royalties and return that value to shareholders. That would imply minimally further share repurchases or some sort of dividend policy out in 2028. But we will work through how to define what to do with the capital. When we actually are cash flow positive in a year from now, there's no intention today to become a royalty consolidator.

Madeline Lee Analyst — UBS

Got it. But that makes sense. And I guess. You know, in the scenario of status quo royalties, would you think about, you know, is there strategic value of the Jim Perley royalty stream to other people who are in the royalty space? We did see some earlier this year consolidation of some of those royalty players. Is that, I guess, a possibility that you think about to the extent you're able to?

Dan Vega CEO

Look, here's the irony of this. We're opportunistic in that we're looking to return value, and that would imply from a fiduciary perspective there's someone that's a better custodian and a broader portfolio of royalties that these assets could sit in. We're obviously open to that. I mean, the irony here, and this is what's interesting about going to trial, is I spoke publicly because I was questioned by opposing counsel at GSK how we were thinking about these types of things, and I had to acknowledge. We've talked to parties about selling the asset historically. That's part of my job is to always be assessing where there is interest. What's happened in the last year from this year is we've well crossed the billion-dollar threshold. We're now approved in a second indication. As I mentioned earlier, in about a month, we should have a second royalty thread that we'll de-risk, and we're a lot closer to paying down that group cigar. We're now within a year as opposed to multiple years with more certainty of that pay-down date. So the risk profile of our business has changed from where we were when we've had those prior, more formal discussions with royalty consolidators and GSK as well, which is now all in the public domain given the trial.

Madeline Lee Analyst — UBS

Right.

Dan Vega CEO

Which would be pretty atypical to talk about these things so openly.

Madeline Lee Analyst — UBS

Right. And, of course, the value of the royalty stream may be changing potentially. Would there be sort of – do you think about that, like the middle scenario and how that might affect any of those conversations with other royalty players?

Dan Vega CEO

A lot of the way you think about royalty streams is what's the certainty that you have a certain baseline? You know, again, the importance of us of hitting the $1 billion, $2 billion thresholds of having a higher royalty creates a lot of value. So a lot of this is really about certainty that you're getting at certain levels. I mentioned before. If it was a different company that I think is a larger oncology company, there would be more certainty, I think, in Wall Street that GSCA is going to perform in the way they're describing. We feel very confident. We're going to see the monotherapy sales hit those peak levels, which is why we have our own guidance out there, mostly because the data is better. There's quotes from the GSK folks. If physicians see the survival data, they're two times more likely to prescribe Jemperle over Keytruda, given the survival advantage in the mitral cancer. We are the only drug approved in rectal. We do expect a very high uptake. So I think the profile of this drug continues to look very favorable. Again, launch in Japan. These things become more certain. Folks will start modeling this differently. I do think it creates a lot of value from relative to where we are sitting here in the mid-40s per share today.

Madeline Lee Analyst — UBS

Got it. I guess in our very last minute, as you said, you presented at oral arguments, October 20th, I think the Chancellor made some comments about there's a lot of material to work through. You said decision sort of any time now between Q1? Is that still the expectation?

Dan Vega CEO

I think Austin GSK may find out within 30 minutes before the public finds out. This is litigation. They will post the decision when they post the decision. We don't have, no one has any better information. Our best way to think about guidance is somewhere in, given what the chancellor said, is I need at least multiple months, sometime in December or January is our best guess. It comes with error bars.

Madeline Lee Analyst — UBS

Got it. Well, thank you so much for being here and for helping us close out our first Linden Bioformer company.

Analyst Q&A · 1 question
Full-screen source Call document